Phase
Condition
Non-small Cell Lung Cancer
Treatment
Nivolumab
Pemetrexed
Cisplatin
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Participants must have NSCLC with Stage IV or recurrent disease following multimodaltherapy for locally advanced disease.
Study treatment must be first-line therapy for Stage IV or recurrent disease.
Participants in all parts of the study must have:
measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1. (RECIST v1.1)
an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
a life expectancy of at least 3 months at the time of first dose
Exclusion
Exclusion Criteria:
Untreated symptomatic central nervous system metastases
Participants with epidermal growth factor receptor (EGFR)/ALK receptor tyrosinekinase (ALK)/ROS proto-oncogene 1 (ROS1)/neurotrophic tyrosine receptor kinase (NTRK)/MET proto-oncogene (MET)/B-Raf proto-oncogene (BRAF)/RET proto-oncogene (RET)mutations amenable to targeted therapies
Participants with any known medical condition that, in the investigator's opinion,would increase the risk associated with study participation or study drugadministration or interfere with the interpretation of safety results
Note: Other protocol-defined inclusion/exclusion criteria apply.
Study Design
Connect with a study center
Local Institution - 0001
Rio Cuarto, Cordoba 5800
ArgentinaSite Not Available
Local Institution - 0022
Cordoba City, Provincia De Cordoba X5004FHP
ArgentinaSite Not Available
Local Institution - 0002
Viedma, Rio Negro 8500
ArgentinaSite Not Available
Local Institution - 0020
Buenos Aires, 11 99
ArgentinaSite Not Available
Local Institution - 0013
St Leonards, New South Wales 2065
AustraliaSite Not Available
Local Institution - 0021
Tweed Heads, New South Wales 2485
AustraliaSite Not Available
Local Institution - 0032
Joondalup, Western Australia 6027
AustraliaSite Not Available
Local Institution - 0043
Vina Del Mar, Valparaiso 252 0598
ChileSite Not Available
Local Institution - 0054
Paris Cedex 05, Ile De France 75005
FranceSite Not Available
Local Institution - 0009
Parma, 43125
ItalySite Not Available
Local Institution - 0006
Rome, 00128
ItalySite Not Available
Local Institution - 0056
Krakow, Malopolskie 31-826
PolandSite Not Available
Local Institution - 0015
Gdansk, Pomorskie 80-952
PolandSite Not Available
Local Institution - 0066
Cluj-Napoca, Cluj 400132
RomaniaSite Not Available
Local Institution - 0062
Cluj-Napoca, 400015
RomaniaSite Not Available
Local Institution - 0060
Cluj-napoca, 400641
RomaniaSite Not Available
Local Institution - 0061
Craiova, 200347
RomaniaSite Not Available
Local Institution - 0065
Floresti, 407280
RomaniaSite Not Available
Local Institution - 0027
Madrid, 28040
SpainSite Not Available
Local Institution - 0038
Glendale, California 37219
United StatesSite Not Available
Los Angeles Cancer Research
Glendale, California 37219
United StatesActive - Recruiting
Clermont Oncology Center
Clermont, Florida 34711
United StatesActive - Recruiting
Local Institution - 0044
Clermont, Florida 34711
United StatesSite Not Available
Local Institution - 0040
Orange City, Florida 32763
United StatesSite Not Available
Mid Florida Hematology and Oncology Center
Orange City, Florida 32763
United StatesActive - Recruiting
Local Institution - 0058
Boise, Idaho 83706
United StatesSite Not Available
Saint Alphonsus Regional Medical Center
Boise, Idaho 83706
United StatesActive - Recruiting
Local Institution - 0041
Baltimore, Maryland 21201-1544
United StatesSite Not Available
MAYO
Rochester, Minnesota 55905
United StatesSite Not Available
The Medical University of South Carolina
Charleston, South Carolina 29425
United StatesSite Not Available
Local Institution - 0049
Houston, Texas 77090
United StatesSite Not Available
Millennium Research & Clinical Development
Houston, Texas 77090
United StatesActive - Recruiting
Swedish Cancer Institute
Seattle, Washington 98275
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.